April 18, 2011
RELEASE: For Immediate Release
PEGASUS ACQUIRES U.S. PATENT FOR ITS HEARTVUE 6S SCREENING DEVICE; APPOINTS TWO EUROPEAN DISTRIBUTORS.
Palm Beach Gardens, FL, Market Wire, April 19th, 2011. Pegasus/HeartView LLC, (Symbol: PGUZ-OTC), today announced that they have acquired a U.S. Patent Number #US 7,519,416, titled "Diagnostic Method Utilizing Standard Lead ECG Signals" for its HeartVue 6S Screening Device.
This development will now initiate procedures to acquire FDA approval prior to marketing efforts of the system in the United States. The HeartVue 6S System is an advanced technology that analyzes low amplitude ECG oscillations (ECG dispersion mapping) and reports them as myocardial micro-alternation indexes (MMI). The HeartVue 6S System provides a non-invasive assessment of heart disease in 30 seconds, utilizing only 4 limb electrodes. The results are then presented as a color-coded, three dimensional digital heart map, which reflects electrical dispersions.
After acquiring a CE Mark Approval for the marketing of the 6S Screening Device in Europe, the Company has now subsequently appointed two distributors to roll out marketing/sales efforts in their respective territories.
For more information, contact Daniel P. Kesonen, Chairman & CEO of Pegasus Pharmaceuticals Inc., Palm Beach Gardens, FL at (561) 626-9901.
Visit the Company's website: www.pegasusbiosciences.com.
We seek Safe Harbor.